Inhibitor Therapeutics Inc 's

• HPPI's Stock Performance relative to its Competitors

Janux Therapeutics Inc Share Performance +19.80% This Quarter

Janux Therapeutics Inc Profile Janux Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative cancer treatments. Their business model revolves around leveraging their expertise in immunotherapies and bispecific antibody platforms to create novel therapies that target tumor cells and activate the patient's immune system. By partnering with pharmaceutical companies and conducting clinical trials, they aim to bring effective and personalized cancer treatments to market. More about Janux Therapeutics Inc 's Market Share

Xoma Royalty Corporation Share Performance +56.49% One Year

Xoma Royalty Corporation Profile Xoma Corporation operates under a business model focused on the development and commercialization of novel therapeutics. The company primarily concentrates on creating antibody-based therapies to address unmet medical needs. Xoma also engages in collaborations and partnerships with other pharmaceutical companies to advance their product pipeline and expand their reach in the market. More about Xoma Royalty Corporation's Market Share

Urogen Pharma Ltd Share Performance +46.33% This Quarter

Urogen Pharma Ltd Profile Urogen Pharma Ltd is a pharmaceutical company that specializes in developing and commercializing innovative therapies for urological and oncological conditions. Their business model revolves around conducting extensive research and development to create novel therapies, obtaining necessary regulatory approvals, and strategically partnering with healthcare providers and other stakeholders to market and distribute their products globally. By focusing on addressing unmet medical needs in the urology field, Urogen Pharma aims to improve patient outcomes and establish a strong presence in the market. More about Urogen Pharma Ltd 's Market Share

Enliven Therapeutics Inc Share Performance -14.50% Over The Past 5 Days

Enliven Therapeutics Inc Profile Enliven Therapeutics Inc's business model focuses on developing and providing effective therapeutic solutions that enhance patient wellness and quality of life. More about Enliven Therapeutics Inc 's Market Share

Nuvectis Pharma inc Share Performance -3.99% Over The Past 5 Days

Nuvectis Pharma inc Profile Nuvectis Pharma Inc's business model appears to focus on the development and commercialization of pharmaceutical products. More about Nuvectis Pharma inc 's Market Share

Sources: Inhibitor Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Thursday, September 17, 2026 9:30 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Inhibitor Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.